Daniel C Yee1,2, Debasree Banerjee1,2, Sara E Vargas3,4, Melissa Allahua1, Mary E Whittenhall1,2, Nicholas Perry3,4, Corey E Ventetuolo1,2,5, Kate M Guthrie3,4. 1. Division of Pulmonary, Critical Care & Sleep Medicine, Rhode Island Hospital, Providence, Rhode Island. 2. Department of Medicine and. 3. Department of Psychiatry and Human Behavior, Warren Alpert Medical School, and. 4. Center for Behavioral and Preventive Medicine, The Miriam Hospital, Providence, Rhode Island. 5. Department of Health Services, Policy & Practice, School of Public Health, Brown University, Providence, Rhode Island; and.
Abstract
Rationale: Health-related quality of life in patients with pulmonary arterial hypertension (PAH) has become increasingly important in disease management as numerous treatment options have improved prognosis and time to clinical worsening. Sexual health-related quality of life (SHRQoL) is poorly understood in patients with PAH, but previous work has shown that patients may face unrecognized challenges, especially related to parenteral prostanoid analogue therapies. Objectives: Using qualitative methods, to describe challenges and perspectives related to SHRQoL among women with PAH. Methods: We conducted 13 semistructured in-depth interviews at the Pulmonary Hypertension Association's International Pulmonary Hypertension Conference and Scientific Sessions among female attendees with World Symposium on Pulmonary Hypertension group 1 PAH. A coding structure using both deductive and inductive coding was developed to organize and analyze data using applied thematic analysis. Salient themes were identified and are presented here using summary and illustrative quotations. Results: Ninety-two percent (12 of 13) of participants reported declines in the frequency of sex after diagnosis of PAH. A significant portion (62% [8 of 13]) experienced fear of having sexual intercourse because of cardiopulmonary symptoms. All participants (100% [13 of 13]) reported compensatory behaviors/strategies during and around sexual intercourse; some participants on subcutaneous prostanoids also reported timing intercourse to coincide with infusion site changes and, as a result, interrupted treatment during this time. Participants reported changing positions during sex to reduce breathlessness, and some reported removing oxygen to avoid interrupting intimacy. Most participants endorsed negative body image related to their medications, external oxygen supplementation, and/or body weight fluctuations (54% [7 of 13]). Many participants revealed that they had never discussed sexual practices with healthcare professionals and desired increased communication and discussion with their providers. Conclusions: Women with PAH face significant burdens and challenges regarding SHRQoL. PAH therapies directly affect SHRQoL. Further targeted qualitative and quantitative studies are needed to better characterize and improve SHRQoL in patients with PAH.
Rationale: Health-related quality of life in patients with pulmonary arterial hypertension (PAH) has become increasingly important in disease management as numerous treatment options have improved prognosis and time to clinical worsening. Sexual health-related quality of life (SHRQoL) is poorly understood in patients with PAH, but previous work has shown that patients may face unrecognized challenges, especially related to parenteral prostanoid analogue therapies. Objectives: Using qualitative methods, to describe challenges and perspectives related to SHRQoL among women with PAH. Methods: We conducted 13 semistructured in-depth interviews at the Pulmonary Hypertension Association's International Pulmonary Hypertension Conference and Scientific Sessions among female attendees with World Symposium on Pulmonary Hypertension group 1 PAH. A coding structure using both deductive and inductive coding was developed to organize and analyze data using applied thematic analysis. Salient themes were identified and are presented here using summary and illustrative quotations. Results: Ninety-two percent (12 of 13) of participants reported declines in the frequency of sex after diagnosis of PAH. A significant portion (62% [8 of 13]) experienced fear of having sexual intercourse because of cardiopulmonary symptoms. All participants (100% [13 of 13]) reported compensatory behaviors/strategies during and around sexual intercourse; some participants on subcutaneous prostanoids also reported timing intercourse to coincide with infusion site changes and, as a result, interrupted treatment during this time. Participants reported changing positions during sex to reduce breathlessness, and some reported removing oxygen to avoid interrupting intimacy. Most participants endorsed negative body image related to their medications, external oxygen supplementation, and/or body weight fluctuations (54% [7 of 13]). Many participants revealed that they had never discussed sexual practices with healthcare professionals and desired increased communication and discussion with their providers. Conclusions: Women with PAH face significant burdens and challenges regarding SHRQoL. PAH therapies directly affect SHRQoL. Further targeted qualitative and quantitative studies are needed to better characterize and improve SHRQoL in patients with PAH.
Entities:
Keywords:
patient-centered care; prostanoid analogue–related side effects; pulmonary arterial hypertension; quality of life; sexual health–related quality of life
Authors: Glenn N Levine; Elaine E Steinke; Faisal G Bakaeen; Biykem Bozkurt; Melvin D Cheitlin; Jamie Beth Conti; Elyse Foster; Tiny Jaarsma; Robert A Kloner; Richard A Lange; Stacy Tessler Lindau; Barry J Maron; Debra K Moser; E Magnus Ohman; Allen D Seftel; William J Stewart Journal: Circulation Date: 2012-01-19 Impact factor: 29.690
Authors: Darren B Taichman; Jennifer Shin; Laryssa Hud; Christine Archer-Chicko; Sandra Kaplan; Jeffery S Sager; Robert Gallop; Jason Christie; John Hansen-Flaschen; Harold Palevsky Journal: Respir Res Date: 2005-08-10
Authors: Debasree Banerjee; Sara E Vargas; Kate M Guthrie; Brittany M Wickham; Melissa Allahua; Mary E Whittenhall; Amy J Palmisciano; Corey E Ventetuolo Journal: Pulm Circ Date: 2018 Oct-Dec Impact factor: 3.017